Skip to main content
editorial
. 2022 Feb 25;52(4):320–323. doi: 10.4070/kcj.2022.0022

Figure 2. The MASTER-DAPT trial: net clinical benefit of abbreviated vs. stardard DAPT in patients with an OAC indication (left) and without an OAC indication (right).

Figure 2

BARC = Bleeding Academic Research Consortium; DAPT = dual antiplatelet therapy; MASTER-DAPT = Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen; MI = myocardial infarction; NNH = number needed to harm; NNT = number needed to treat; OAC = oral anticoagulant.